Wells Pharmacy Recalls Testosterone and Anastrazole Pellets Due to Potency Issues
Wells Pharmacy Network is recalling Testosterone 200 mg/Anastrazole 20mg Pellets because they may be superpotent or subpotent.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls with potential for significant harm or hospitalization reports are scored as Severe (4).
Plain-English summary
Wells Pharmacy Network, LLC is recalling Testosterone 200 mg/Anastrazole 20mg Pellets. The recall is being conducted because the product may be superpotent or subpotent. The affected product consists of 318 pellets with Lot Number 08162016@5 and a beyond-use date of 02/12/2017.
The recall is classified as Class II by the U.S. Food and Drug Administration. The distribution pattern is listed as U.S. Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- Testosterone 200 mg/Anastrazole 20mg Pellet, Compounded by: Wells Pharmacy Network
- Manufacturer
- Wells Pharmacy Network, LLC
- Category
- Drug — Compounded Medication
- Hazard
- Affected units
- 318
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number 08162016@5
- BUD: 02/12/2017
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 7 recalled by Wells Pharmacy Network, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Wells Pharmacy Network, LLC
See all →- SevereWells Pharmacy Recalls Injectable Compounds Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Chorionic Gonadotropin Injectable Kits
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Trimix with Atropine Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Testosterone Cypionate Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
Same hazard · potency issues
See all →- SevereIngenus Recalls Irinotecan Hydrochloride Injection Due to Potency Issues
FDA (Drugs) · 2018-07-11
- LowApotex Recalls Aripiprazole Tablets Due to Potential Potency Issues
FDA (Drugs) · 2017-02-15
- ModerateWells Pharmacy Recalls Testosterone Pellets Due to Potency Issues
FDA (Drugs) · 2016-11-16
Similar recalls
- SevereTestosterone and Anastrazole Pellets Recalled for Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereFDA Recalls Testosterone and Anastrazole Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-09-23
- SevereWells Pharmacy Recalls Testosterone Cypionate Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereFDA Recalls Testosterone/Anastrozole Pellets Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereQualgen Testosterone and Anastrozole Pellets Recalled for Sterility Concerns
FDA (Drugs) · 2018-11-14
- ModerateMasterPharm Recalls Testosterone/Anastrozole Pellets Due to Processing Control Deficiencies
FDA (Drugs) · 2020-08-05